Authors
Latest:
Dr. Mayer Fishman on New Treatment Combination for Patients with Metastatic Chemo-Refractory Urothelial CancerMayer Fishman, MD, PhD, Medical Oncologist, Moffitt Cancer Center, talks about the phase Ib/II study of an IL-2/T-cell receptor fusion protein in combination with gemcitabine and cisplatin in advanced or metastatic chemo-refractory urothelial cancer (UC).
Latest:
Emerging Approaches for Gastric/GEJ Cancers Take the Spotlight at ASCO GIEmerging treatments, particularly claudin 18.2, a potential new biomarker in the HER2-negative gastric and gastroesophageal junction cancer space, were highlights of the 2023 ASCO Gastrointestinal Cancers Symposium.
Latest:
Defining a Negative Margin After Breast Conservation SurgeryMeena Savur Moran, MD, professor, therapeutic oncology, and director of the radiation therapy breast program, Smilow Cancer Hospital at Yale-New Haven, discusses the margin guidelines that have been identified in breast conservation.
Latest:
Considerations When Treating Breast Cancer in Patients of Different Ethnic BackgroundsMeena Savur Moran, MD, radiation oncologist, professor, Therapeutic Radiology, director, Breast Cancer Radiotherapy Program, Yale Cancer Center, discusses considerations oncologists take when treating patients with breast cancer of different ethnic backgrounds.
Latest:
Consolidation to VRD Improves PFS in Patients With Newly Diagnosed MyelomaConsolidation therapy with bortezomib/lenalidomide/dexamethasone (VRD) followed by maintenance with lenalidomide until progression or toxicity showed promising results over maintenance alone for patients with transplant-eligible multiple myeloma (NDMM) up to 65 years old, according to a final analysis of the EMN02 trial.
Latest:
Sipuleucel-T Shows Potential With New Trial Data, But Questions Regarding Clinical Relevance RemainSince the approval of sipuleucel-T for the treatment of minimally symptomatic metastatic castration-resistant prostate cancer in 2010, barriers to administration and the approval of competing drugs has tampered wide adoption of its use.
Latest:
The Impact of FLT3 Inhibitors for the Treatment of AMLMeir Wetzler, MD, from Roswell Park Cancer Institute, discusses the potential impact of FLT3 inhibitors for the treatment of patients with acute myeloid leukemia.
Latest:
Adjuvant Capecitabine/Gemcitabine for EHCC and GBCAMelanie B. Thomas, MD, discusses the rationale of a phase II study of adjuvant capecitabine/gemcitabine for extrahepatic cholangiocarcinoma and gallbladder carcinoma.
Latest:
Overview of Merkel Cell CarcinomaMerkel cell carcinoma (MCC) is a rare but potentially lethal skin cancer that has traditionally been treated with surgery, radiation, and in advanced cases, chemotherapy. Patients with even localized disease have a high risk of recurrence and those who develop metastatic disease have had a poor overall survival.
Latest:
The Future of NDMM: Ongoing Studies and Current Challenges in the LandscapeMelissa Alsina, MD cites recent data from ongoing studies as well as highlights remaining questions and unmet needs in the NDMM landscape.
Latest:
Natural Language Processing in Diagnosis of Lung CancerMelissa Johnson, MD, associate director, Lung Cancer Research, Sarah Cannon Research Institute, discusses the use of natural language processing in the diagnosis of lung cancer.
Latest:
Outcomes and Guidelines for MRI in Patients With DCISMelissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, comments on outcomes and guidelines for MRI in patients with DCIS.
Latest:
Dr. Silverstein Discusses the Benefits of Oncoplastic Surgery for Patients With Breast CancerMelvin J. Silverstein, MD, FACS, Hoag Memorial Hospital Presbyterian, discusses the benefits of oncoplastic surgery for patients with breast cancer.
Latest:
The dtect<em>Dx</em> Breast Test for Breast CancerMeredith C. Henderson, PhD, Head, R&D, Provista Diagnostics, describes the dtectDx Breast test.
Latest:
Areas of Controversy in the Treatment Landscape of mCRCMichael A. Choti, MD, chief of surgery at MD Anderson Cancer Center, discusses some controversial topics he sees in the treatment landscape of metastatic colorectal cancer.
Latest:
Dr. Michael A. Davies on Identifying Patients With Melanoma at Risk for Developing Brain Metastases​Michael A. Davies, MD, PhD, discusses the importance of identifying which patients diagnosed with melanoma are at the highest risk for developing brain metastases.
Latest:
A Look Inside the Toolbox for BRAF-Mutant Metastatic MelanomaIn season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.
Latest:
Dr. Michael Atkins on Benefits of Adjuvant Treatment in MelanomaAtkins says because treatments currently used in patients with visible metastatic melanoma are normally efficacious between 50% and 60% of the time, then the expectation for these treatments in the adjuvant setting could be effective around 80% of the time.
Latest:
Investigative Treatments for Metastatic MelanomaDr Atkins discusses current unmet needs in the treatment landscape for metastatic melanoma and provides an overview of some of the treatments currently under investigation that show promise.
Latest:
Dr. Baumann on Hypoxia-Specific PET Imaging in Head and Neck CancerMichael Baumann, MD, Professor of Radiation Oncology, Director University of Dresden Cancer Center in Dresden, Germany discusses the DDFMISO-trial, which investigated hypoxia-specific PET imaging during radio-chemotherapy for locally advanced head-and-neck cancer.
Latest:
Novel Treatment Strategies in Endometrial CancerClosing out their program on endometrial carcinoma management, key opinion leaders highlight key novel therapeutic strategies in the evolving treatment landscape.
Latest:
Prolaris Testing in Men With Clinically Localized Prostate CancerMichael Brawer, MD, vice president, Medical Affairs, Myriad Genetic Laboratories, discusses Prolaris testing in men who have clinically localized prostate cancer.
Latest:
Implementing a Lung Cancer Screening Program in the Community Oncology SettingMichael Gieske, MD, discusses how his community center was able to implement a lung cancer screening program.
Latest:
PARP Inhibitor Olaparib Exceeds Expectations in BRCA+ Pancreatic Cancer ManagementPancreatic cancer with <em>BRCA1</em>and <em>BRCA2 </em>mutations has shown positive responses to the PARP inhibitor olaparib in preliminary trials.
